AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With MetastaticNeuroendocrine Neoplasm

NCT03453489 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

4

Enrollment

OTHER

Sponsor class

Conditions

Carcinoid Syndrome
Metastatic Nonfunctional Well Differentiated Neuroendocrine Neoplasm

Interventions

OTHER: Carbon C 11 Alpha-methyltryptophan
OTHER: Laboratory Biomarker Analysis
PROCEDURE: Positron Emission Tomography
DRUG: Telotristat Etiprate

Sponsor

Barbara Ann Karmanos Cancer Institute

Collaborators

[object Object]